|LETTER TO THE EDITOR
|Year : 2022 | Volume
| Issue : 4 | Page : 613
New COVID-19 vaccine, thiomerosol, and reversible cerebral vasoconstriction
Rujittika Mungmunpuntipantip1, Viroj Wiwanitkit2
1 Private Academic Consultant, Bangkok, Thailand
2 Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India
|Date of Submission||29-May-2021|
|Date of Decision||09-Jul-2021|
|Date of Acceptance||30-Jul-2021|
|Date of Web Publication||07-Mar-2022|
Private Academic Consultant, Bangkok
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Mungmunpuntipantip R, Wiwanitkit V. New COVID-19 vaccine, thiomerosol, and reversible cerebral vasoconstriction. Med J DY Patil Vidyapeeth 2022;15:613
|How to cite this URL:|
Mungmunpuntipantip R, Wiwanitkit V. New COVID-19 vaccine, thiomerosol, and reversible cerebral vasoconstriction. Med J DY Patil Vidyapeeth [serial online] 2022 [cited 2022 Aug 11];15:613. Available from: https://www.mjdrdypv.org/text.asp?2022/15/4/613/339182
COVID-19 vaccine is the hope for containment of COVID-19 pandemic. In preventive medicine, the vaccination is the best primary prevention of infectious disease. The new COVID-19 vaccine usually receives a registration certificate under emergency rules adopted during the COVID-19 pandemic, and there are limited data on efficacy and adverse effect of the new vaccine. Different COVID-19 vaccines might have different efficacies and adverse effects.
Focusing on the possible adverse effect of COVID-19 vaccine, there are some reports on neurological problems after COVID-19 vaccination. A reversible cerebral vasoconstriction might be observed in some persons receiving inactivated COVID-19 vaccine. The reversible cerebral vasoconstriction is a rare adverse effect of some vaccines such as measles vaccine. For a noninactivated COVID-19 vaccine, it might induce viscosity change and result in a thrombohemostatic disorder. Coagulation risk with the adenoviral vector vaccines is also related to induction of antibody to platelet factor 4. Nevertheless, the pathogenesis of neurological deficit due to inactivated COVID-19 vaccine is unknown.
Regarding the adverse effect due to COVID-19 vaccine, a component of the vaccine might play an important role. In a recent study, the component of COVID-19 vaccine is associated with an allergic adverse effect. Regarding inactivated vaccine, thimerosal is a component that might be related to adverse effect. Thimerosal is a mercury compound used as a composition of inactivated COVID-19 vaccine. It can cause allergic-like reaction at skin. The vasoconstriction effect of thimerosal is also reported, and it might be associated with reversible cerebral vasoconstriction after inactivated COVID-19 vaccination. Further studies on this issue are recommended.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Hamano T, Takeda T, Morita H, Muramatsu T, Yoneda M, Kimura H, et al.
Posterior reversible encephalopathy syndrome following measles vaccination. J Neurol Sci 2010;298:124-6.
Geeraerts T, Montastruc F, Bonneville F, Mémier V, Raposo N, Toulouse Vitt Study Group. Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience. Anaesth Crit Care Pain Med 2021;40:100889.
Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al.
Allergic reactions to current available COVID-19 vaccinations: Pathophysiology, causality, and therapeutic considerations. Vaccines (Basel) 2021;9:221.
Peng B, Che D, Hao Y, Zheng Y, Liu R, Qian Y, et al.
Thimerosal induces skin pseudo-allergic reaction via Mas-related G-protein coupled receptor B2. J Dermatol Sci 2019;95:99-106.
Lemos NB, Angeli JK, Faria Tde O, Ribeiro Junior RF, Vassallo DV, Padilha AS, et al.
Low mercury concentration produces vasoconstriction, decreases nitric oxide bioavailability and increases oxidative stress in rat conductance artery. PLoS One 2012;7:e49005.